Pfizer says delaying drug price hikes after Trump conversation


WASHINGTON (Reuters) – Pfizer Inc (PFE.N) said on Tuesday it was deferring drug price increases for no more than six months after the company’s chief executive officer had an extensive conversation with U.S. President Donald Trump.

FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly

Pfizer said it would defer price increases that went into effect on July 1 until the end of the year or until the president’s drug pricing blueprint goes into effect – whichever is sooner. The company said it would return drug…



Read More Here

Be the first to comment on "Pfizer says delaying drug price hikes after Trump conversation"

Leave a comment

Your email address will not be published.


*